Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Injectable WCK 4282 (FEP-TAZ) in Healthy Adult Human Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Cefepime/tazobactam (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- 18 May 2016 New trial record
- 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (2016).